IP Verse

Cellectis competitive analysis

Latest patents of Cellectis opposed by its competitors

Explore Cellectis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 16, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3189073
Jun 11, 2025Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP4368705
Jan 1, 2025Method For Generating T-Cells Compatible For Allogenic Transplantation4
EP2997141
Oct 12, 2022Cd19 Specific Chimeric Antigen Receptor And Uses Thereof1
EP3116902
Jan 1, 2020Method For Generating T-Cells Compatible For Allogenic Transplantation4
EP3126390
Oct 16, 2019Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP3008186
Nov 28, 2018Methods For Non-Transgenic Genome Editing In Plants4
EP3105317
Sep 19, 2018Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells2
EP3004349
Mar 28, 2018A Method For Producing Precise Dna Cleavage Using Cas9 Nickase Activity1
EP3004337
Aug 2, 2017Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease System1

Latest publications and patents of Cellectis New

Explore the latest publications and patents granted to Cellectis, showcasing their recent innovations and technological advancements.

Last updated on: Oct 14, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Cellectis

EP3189073
Jun 11, 2025Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer ImmunotherapyPatent Maintained As Amended
EP4368705
Jan 1, 2025Method For Generating T-Cells Compatible For Allogenic TransplantationGranted And Under Opposition
EP2997141
Oct 12, 2022Cd19 Specific Chimeric Antigen Receptor And Uses ThereofGranted And Under Opposition
EP3116902
Jan 1, 2020Method For Generating T-Cells Compatible For Allogenic TransplantationRevoked
EP3126390
Oct 16, 2019Cd33 Specific Chimeric Antigen Receptors For Cancer ImmunotherapyGranted And Under Opposition
EP3008186
Nov 28, 2018Methods For Non-Transgenic Genome Editing In PlantsRevoked
EP3105317
Sep 19, 2018Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological CellsOpposition Rejected
EP3004349
Mar 28, 2018A Method For Producing Precise Dna Cleavage Using Cas9 Nickase ActivityGranted And Under Opposition
EP3004337
Aug 2, 2017Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease SystemOpposition Rejected

Latest PTAB cases involving Cellectis

Discover the latest PTAB cases involving Cellectis, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Cellectis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 16, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
CELLECTIS - 20 - -
BARKER BRETTELL5 - - -
CENTURY THERAPEUTICS3 - - -
JAMES POOLE153 - - -